MORRISVILLE, N.C.--(BUSINESS WIRE)--July 17, 2006--BioDelivery Sciences International, Inc. (NASDAQ:BDSI - News), a specialty biopharmaceutical company, has submitted a plan to the United States Food and Drug Administration (FDA) to conduct two clinical pharmacokinetic studies regarding the company's Emezine® (prochlorperazine maleate) buccal tablets. This plan was submitted for FDA review in response to the company's previously announced meeting with the FDA regarding Emezine®.
